Skip to content

Psilocybin: all studies

Page 276 of 440: studies 2,751 to 2,760 of 4,392, newest first. Back to the psilocybin overview

Research

The use of illicit drugs as self-medication in the treatment of cluster headache: Results from an Italian online survey

Cephalalgia April 22, 2015 Cherubino Di Lorenzo, Gianluca Coppola, Giorgio Di Lorenzo et al. 40 citations

Background Cluster headache (CH) patients often receive unsatisfactory treatment and may explore illicit substances as alternatives. We aimed to explore this use of illicit drugs for CH treatment. Methods We invited CH patients from an Internet-based self-help group to complete a questionnaire regarding their therapeutic use of illicit substances. Results Of the 54 respondents, 29 were...

Discovery of a new caerulescent Psilocybe mushroom in Germany: Psilocybe germanica sp.nov.

Drug Testing and Analysis March 31, 2015 Jochen Gartz, Georg Wiedemann 13 citations

Sixty years ago, the ethnomycologist R. G. Wasson discovered an ancient mushroom cult in Oaxaca, Mexico. 1, 2 The famous mycologist R. Heim classified the psychoactive mushroom species in the genera Psilocybe and the eminent natural product chemist Albert Hofmann published the isolation, structural elucidation and synthesis of the new alkaloids psilocybin and psilocin in 1958. These indole...

DOI: 10.1002/dta.1795 (opens in new tab) Psilocybin Mushroom Indole alkaloid Botany +1

Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population.

Journal of Psychopharmacology March 1, 2015 Peter S. Hendricks, Christopher B Thorne, C Brendan Clark et al. 377 citations

Mental health problems are endemic across the globe, and suicide, a strong corollary of poor mental health, is a leading cause of death. Classic psychedelic use may occasion lasting improvements in mental health, but the effects of classic psychedelic use on suicidality are unknown. We evaluated the relationships of classic psychedelic use with psychological distress and suicidality among over...

The Effect of 5-HT2A/1a Agonist Treatment On Social Cognition, Empathy, and Social Decision-making

European Psychiatry March 1, 2015 Katrin H. Preller, Thomas Pokorny, Rainer Krähenmann et al. 20 citations

Social cognition is a crucial factor influencing development, progress, and treatment of psychiatric disorders. However, social cognition skills are insufficiently targeted by current treatment approaches. In particular, patients suffering from depression show an increased negative reaction to social exclusion and deficits in empathy. The 5HT-1A/2A receptor agonist psilocybin has previously...

Psychedelics not linked to mental health problems or suicidal behavior: A population study

Journal of Psychopharmacology March 1, 2015 Pål-ørjan Johansen, Teri Suzanne Krebs 300 citations

A recent large population study of 130,000 adults in the United States failed to find evidence for a link between psychedelic use (lysergic acid diethylamide, psilocybin or mescaline) and mental health problems. Using a new data set consisting of 135,095 randomly selected United States adults, including 19,299 psychedelic users, we examine the associations between psychedelic use and mental...

Salvador Roquet, María Sabina, and the Trouble withJipis

Hispanic American Historical Review February 1, 2015 Alexander S. Dawson 16 citations

Abstract While María Sabina has long been an iconic figure among drug enthusiasts and advocates for indigenous rights, her sometime collaborator Salvador Roquet remains largely unknown. This essay introduces the work of this iconoclastic psychiatrist and, in particular, his work with Sabina, highlighting their contributions to the world of psychedelic psychiatry and exploring the nature of...

Drug models of schizophrenia.

Therapeutic Advances in Psychopharmacology February 1, 2015 Hannah Steeds, Robin Carhart-Harris, James Stone 132 citations

Schizophrenia is a complex mental health disorder with positive, negative and cognitive symptom domains. Approximately one third of patients are resistant to currently available medication. New therapeutic targets and a better understanding of the basic biological processes that drive pathogenesis are needed in order to develop therapies that will improve quality of life for these patients....

Legal highs: staying on top of the flood of novel psychoactive substances

Therapeutic Advances in Psychopharmacology January 26, 2015 David Baumeister, Luis M. Tojo, Derek K. Tracy 158 citations

There has been growing clinical, public, and media awareness and concern about the availability and potential harmfulness of so-called ‘legal highs’, which are more appropriately called new or novel psychoactive substances (NPS). A cat-and-mouse process has emerged wherein unknown chemists and laboratories are producing new, and as yet nonproscribed, compounds for human consumption; and as soon...

New World Tryptamine Hallucinogens and the Neuroscience of Ayahuasca

Current Topics in Behavioral Neurosciences 2015 Dennis J. Mckenna, Jordi Riba 31 citations

New World indigenous peoples are noted for their sophisticated use of psychedelic plants in shamanic and ethnomedical practices. The use of psychedelic plant preparations among New World tribes is far more prevalent than in the Old World. Yet, although these preparations are botanically diverse, almost all are chemically similar in that their active principles are tryptamine derivatives, either...

‘Riding the Lines’: The Poetics of the ‘Chevauchements’ in Henri Michaux’s Drug Experiments

Palgrave Macmillan UK eBooks 2015 Mathieu Perrot 1 citation

In 1954, at the age of 55, Henri Michaux was a well-published writer and a seasoned traveller. As a young man in the 1930s and 1940s, the Belgian poet and painter had voyaged across East Asia, Central and South America, which resulted in a large portion of his oeuvre: well-known accounts, both real and imaginary, of his trips abroad, fictional ethnographies, and numerous volumes of poetry....